*5.3.5.4 Other oral Janus kinase inhibitors under investigation*

It is a phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral JAKi drugs ritlecitinib and brepocitinib in patients with severe AA (SALT >50%). The trial includes 47 patients in each study group [104]. Results at week 24 suggest efficacy of riclecitinib and brepocitinib in AA, although two patients experienced a serious adverse event (rhabdomyolysis) in the brepocitinib group [104].
